---

Radioligand Therapy: Seizing The Opportunity

Radioligand therapies (RLTs) are an emerging class of targeted therapies that could transform the way some cancers (several of which have large eligible patient populations such as breast, lung, and hematologic cancers) are treated. The RLT market is expected to grow significantly over the course of this decade, with increasing interest in this modality from the academic, clinical and investor communities. Although there are a number of compelling growth drivers for the RLT market overall, there are also several challenges that will need to be overcome if the market is to achieve its full potential. In this white paper we explore the potential for RLT to transform the oncology landscape, and consider the scientific, clinical and commercial requirements for success.

Download whitepaper Radioligand Therapy – Seizing The Opportunity